Lanadelumab is a Monoclonal Antibody owned by Takeda Pharmaceutical, and is involved in 22 clinical trials, of which 10 were completed, 11 are ongoing, and 1 is planned.

Lanadelumab (DX-2930, SHP643) is an inhibitor of plasma kallikrein. Plasma kallikrein interferes with the normal blood clotting process in the brain following blood vessel injury. It also mediates inflammation and leads to rapid accumulation of fluid in the interstitium. Plasma kallikrein’s inhibition suppresses the release of bradykinin which is an important mediator of the symptoms of angioedema.

The revenue for Lanadelumab is expected to reach a total of $27.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lanadelumab NPV Report.

Lanadelumab was originated by Dyax and is currently owned by Takeda Pharmaceutical.

Lanadelumab Overview

Lanadelumab (Takhzyro) recombinant, fully human, monoclonal antibody (IgG1/ κ -light chain) produced in Chinese Hamster Ovary (CHO) cells. It is formulated as injectable solution for subcutaneous route of administration. Takhzyro is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients of 12 years and older.

Lanadelumab (DX-2930, SHP643, TAK-743) is under development for the prophylactic treatment of Coronavirus disease 2019 (COVID-19), plasma kallikrein (bradykinin) mediated Hereditary Angioedema (HAE). The therapeutic candidate is administered as subcutaneous and intravenous injection. It is a fully human monoclonal antibody acts by targeting plasma kallikrein. It was also under development for diabetic macular edema and Coronavirus disease 2019 (COVID-19) pneumonia, factor XII-associated cold autoinflammatory syndrome (FACAS).

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Lanadelumab

Report Segments
  • Innovator (NME)
Drug Name
  • Lanadelumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Genetic Disorders
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.